UB-iC200 / Umoja Biopharma - LARVOL DELTA

Umoja Biopharma Presents New Preclinical Data on its Integrated In Vivo CAR T and Engineered Induced Pluripotent Stem Cell Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (GlobeNewswire) - "Umoja Biopharma...announced today new data from three poster presentations at the 2022 Society for Immunotherapy of Cancer 37th Annual Meeting....A third poster highlights Umoja’s best-in-class iPSC-based allogeneic cell therapy platform that utilizes a Synthetic Receptor Enabled Differentiation (ShRED) manufacturing process which employs RACR to direct differentiation and expansion of RACR-induced cytotoxic innate lymphocytes (iCILs)....RACR activation of RACR-iCILs enhances both serial killing of a breast tumor cell line in vitro and tumor clearance in an in vivo breast cancer mouse model."

Preclinical • Breast Cancer • Oncology • Solid Tumor